1. Home
  2. DEI vs SNDX Comparison

DEI vs SNDX Comparison

Compare DEI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Douglas Emmett Inc.

DEI

Douglas Emmett Inc.

HOLD

Current Price

$10.47

Market Cap

1.9B

Sector

Real Estate

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.58

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DEI
SNDX
Founded
1971
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2006
2016

Fundamental Metrics

Financial Performance
Metric
DEI
SNDX
Price
$10.47
$20.58
Analyst Decision
Hold
Strong Buy
Analyst Count
7
13
Target Price
$14.79
$80.23
AVG Volume (30 Days)
2.6M
1.2M
Earning Date
02-10-2026
03-02-2026
Dividend Yield
7.22%
N/A
EPS Growth
N/A
N/A
EPS
0.12
N/A
Revenue
$1,000,336,000.00
$111,304,000.00
Revenue This Year
$2.82
$617.40
Revenue Next Year
$1.47
$115.70
P/E Ratio
$84.47
N/A
Revenue Growth
3.61
595.65
52 Week Low
$10.46
$8.58
52 Week High
$18.61
$22.73

Technical Indicators

Market Signals
Indicator
DEI
SNDX
Relative Strength Index (RSI) 30.41 50.00
Support Level $10.71 $19.79
Resistance Level $10.83 $22.18
Average True Range (ATR) 0.25 1.05
MACD -0.03 -0.08
Stochastic Oscillator 5.52 39.46

Price Performance

Historical Comparison
DEI
SNDX

About DEI Douglas Emmett Inc.

Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: